SCHEMBL15912477

SCHEMBL15912477

CC(=O)C(F)(F)Oc1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
MAOB P27338 3/20 0.40
LDHA P00338 1/20 0.40
GAA P10253 1/20 0.39
EPHX2 P34913 1/20 0.38
ALDH1A1 P00352 3/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAOA P21397 2/20 0.36
CYP1A2 P05177 1/20 0.36
PPARD Q03181 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21612881 0.82 LDHA (0.46) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL15912487 0.78 KMT2A (0.48) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL7908141 0.78 PLK1 (0.38) NPSR1MAPTLMNAMAOBGAA
SCHEMBL15897084 0.78 EPHX2 (0.50) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL16546592 0.73 ALDH1A1 (0.40) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL220074 0.72 MAPT (0.47) MEN1KMT2AMAPTMAOBEPHX2
SCHEMBL3031192 0.72 RAB9A (0.59) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL1811163 0.71 PPARA (0.67) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL30609397 0.71 PPARA (0.37) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL6754623 0.70 PPARA (0.40) MEN1KMT2ANPSR1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 MEN1 1384/4885KMT2A 2450/4885NPSR1 259/4885
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 MEN1 1728/4885KMT2A 1775/4885NPSR1 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.